ATLANTA, March 13 /PRNewswire-FirstCall/ -- CryoLife, Inc. , a biomaterials, medical device and tissue processing company, announced today that the Company has declared a dividend of approximately $0.75 per share on its 6% convertible preferred stock, payable on April 2, 2007, to shareholders of record as of the close of business on March 22, 2007.
About CryoLife
Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.
For additional information about the Company, visit CryoLife's Web site: http://www.cryolife.com
Media Contacts: D. Ashley Lee Katie Brazel Executive Vice President, Fleishman Hillard Chief Financial Officer and Phone: 404-739-0150 Chief Operating Officer Phone: 770-419-3355
CryoLife, Inc.CONTACT: D. Ashley Lee, Executive Vice President, Chief Financial Officerand Chief Operating Officer of CryoLife, Inc., +1-770-419-3355; or KatieBrazel of Fleishman Hillard +1-404-739-0150, for CryoLife, Inc.
Web site: http://www.cryolife.com/